In cooperation with experts in genetic diagnostics,
Devyser proudly presents a series of whitepapers on fragment analysis and next generation sequencing (NGS).
A source of inspiration for laboratory professionals, they offer solid advice on current problems and ideas for future use.
Introduction to QF-PCR
by Dr. Kathy Mann
Authored by Dr. Kathy Mann, the pioneer in prenatal QF-PCR analysis, it includes useful sections on: assay design, sample processing, limitations and much more.
Detecting Mosaicism with
QF-PCR by Dr. Kathy Mann
Authored by Dr. Kathy Mann, the pioneer in prenatal QF-PCR analysis, it includes useful sections on: origin, detection and incidence of mosaicism and more.
QF-PCR and Maternal Cell Contamination by Dr. Kathy Mann
This paper offers solid advice for laboratory professionals on using a QF-PCR-based approach to identify maternal cell contamination in uncultured AF and CV samples.
QF-PCR in Pregnancy Loss Analysis by Dr. Helen White
This paper provides insights for laboratory professionals on the advantages of using extended QF-PCR in the genetic analysis of pregnancy loss samples.
Authored by Dr. Helen White, Senior Clinical Lecturer at the UK National Genetics Reference Laboratory (Wessex).
Overcoming limitations in the detection of mixed chimerism
This paper highlights the importance of chimerism as a diagnostic tool for clinicians treating transplanted patients. Furthermore, the evolution of novel diagnostic tools for early detection of mixed chimerism is discussed.
Authored by Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital, Sweden.
Next Generation Sequencing
NGS: Full Gene Sequencing
of BRCA1 and BRCA2
With the increasing use of NGS, the number of detected variants in BRCA1 and BRCA2 are increasing fast. As a consequence, the absolute numbers of Variants of Uncertain Significance (VUS) are also increasing.
This paper describes current initiatives to classify and interpret VUS in BRCA1 and BRCA2, and how laboratories can contribute to these efforts and ultimately improve the counseling of tested patients.
NGS: Changing the game
in CFTR analysis
Many testing strategies have been developed in laboratories across the world. Optimal strategies generally include what might be termed “level 1” and “level 2” testing. Until the recent application of next generation sequencing (NGS), no single-pass assay has been capable of routinely screening for all published CFTR mutations.
Authored by Stewart Payne, Consultant Clinical Scientist at UK National Health Service and Head of Molecular Genetics in the North West Thames Regional Genetics since 1995.
Familial Hypercholesterolemia: Genetic Diagnosis and Cascade Testing Using NGS